These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33558159)

  • 1. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
    Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
    Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
    BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
    Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
    Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates in Urothelial Carcinomas.
    Sarfaty M; Rosenberg JE
    Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
    Niegisch G
    Methods Mol Biol; 2023; 2684():293-301. PubMed ID: 37410242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
    You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
    Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Alameddine R; Mallea P; Shahab F; Zakharia Y
    Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.